Avacta Provides Q2 2025 Business Update
Why we think this is neutral
This RNS announcement does not contain any of the mandatory news types specified, such as contract news, order news, trading update, financing, funding, annual results, asset sale/disposal, flow testing, licence news, or delisting. Therefore, the sentiment score is set to neutral.
Key Points
- AVA6000 Phase 1b expansion cohorts continue to enroll with encouraging initial signals of efficacy
- Avacta strengthens the Executive Management Team and Board of Directors with multiple additions
Summary
The biotechnology company provides a business update on the progress of its pipeline and changes to its management team and board.
Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, has provided a business update ahead of its Annual General Meeting. The update outlines progress against the company's strategic objectives for 2025, including the continued clinical development of its peptide drug conjugate pipeline and changes to its executive management team and board of directors.
Key Dates
Early 2026
Phase 1 trial for FAP-EXd (AVA6103) anticipated to begin
Q1 2026
Initial data in triple negative breast cancer for FAP-Dox (AVA6000) expected
Late 2025
Initial data in salivary gland cancer for FAP-Dox (AVA6000) expected
GENERAL UPDATE